Beam Therapeutics reports Q3 EPS ($1.17), consensus ($1.13)
PremiumThe FlyBeam Therapeutics reports Q3 EPS ($1.17), consensus ($1.13)
8h ago
BEAM Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
BEAM Upcoming Earnings Report: What to Expect?
2d ago
Beam Therapeutics (BEAM): The Next Frontier in Biotech
Premium
Market News
Beam Therapeutics (BEAM): The Next Frontier in Biotech
19d ago
Beam Therapeutics CEO Evans sells 60,000 common shares
PremiumThe FlyBeam Therapeutics CEO Evans sells 60,000 common shares
1M ago
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
Premium
The Fly
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
1M ago
Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
Premium
The Fly
Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
1M ago
Beam Therapeutics price target lowered to $31 from $33 at Barclays
PremiumThe FlyBeam Therapeutics price target lowered to $31 from $33 at Barclays
3M ago
Beam Therapeutics reports Q2 EPS ($1.11), consensus ($1.13)
Premium
The Fly
Beam Therapeutics reports Q2 EPS ($1.11), consensus ($1.13)
3M ago
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
Premium
Stock Analysis & Ideas
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100